Program
QLS1410
A development code. Also written as “Dose 1 of QLS1410”, “Dose 2 of QLS1410” and “Dose 3 of QLS1410”.
Its studies are mostly in Hypertension · Hyperaldosteronism, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 55 open or running | phase 2since Mar 18, 2026 | Aug 26, 2025 | Dec 2026phase 2 · NCT07489612 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2025First study: phase 1 study in Uncontrolled HypertensionFirst studyNCT07152444 · 78 planned · China
- Jan 7, 2026Phase 1 study in Uncontrolled HypertensionNCT07358858 · 12 planned
- Mar 18, 2026Phase 2 study in HypertensionPhase 2 reachedNCT07489612 · 260 planned · China
- Apr 19, 2026Phase 2 study in HyperaldosteronismNCT07550465 · 60 planned
- Nov 4, 2026Phase 2 study in Uncontrolled HypertensionNCT07927556 · 260 planned
Ahead
- Dec 2026Primary completion: phase 2 study in HypertensionNCT07489612
- Apr 2027Primary completion: phase 2 study in HyperaldosteronismNCT07550465
- Dec 2027Primary completion: phase 2 study in Uncontrolled HypertensionNCT07927556
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07927556Uncontrolled Hypertension | 2 | Not yet recruiting | Dec 2027 | 260 |
| NCT07550465Hyperaldosteronism | 2 | Not yet recruiting | Apr 2027 | 60 |
| NCT07489612Hypertension · China | 2 | By invitation | Dec 2026 | 260 |
| NCT07358858Uncontrolled Hypertension | 1 | Not yet recruiting | Feb 7, 2026 | 12 |
| NCT07152444Uncontrolled Hypertension · China | 1 | Not yet recruiting | May 2026 | 78 |
How it is read
Names in the registry
- “Dose 1 of QLS1410”, 2 entries
- “Dose 2 of QLS1410”, 2 entries
- “Dose 3 of QLS1410”, 2 entries
- “QLS1410”, 2 entries
- “QLS1410 (CYP11B2 inhibitor)”, 1 entry
Codes read as this program: QLS1410.
Conditions, from the studies’ own filings
- Hypertension, 4 studies
- Hyperaldosteronism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.